Analyst Viewpoint
Increase in prevalence of diabetes and technological advancements in diabetic retinopathy surgical instruments are fueling the proliferative diabetic retinopathy market size. Proliferative diabetic retinopathy is one of the leading vision impairments in the geriatric population, thereby requiring early diagnosis and effective treatment. Growth in geriatric population across the globe is propelling the market expansion.
Leading companies in the industry focus on introducing precise drugs and therapies to ensure disease diagnosis at an initial stage and reduce the risk of vision loss. Technological advancements in healthcare sector offer lucrative proliferative diabetic retinopathy market opportunities for the companies operating in this business. Moreover, they conduct clinical trials to receive product approvals from authorized organizations to introduce new products in global markets.
Proliferative Diabetic Retinopathy (PDR) is an advanced stage of diabetic retinopathy, a complication of diabetes that affects the eyes by damaging the blood vessels in the retina. Growth of abnormal blood vessels in the retina can lead to serious vision problems and even blindness if left untreated. High blood pressure, high cholesterol levels, and poorly controlled diabetes may lead to these vision impairments. Proliferative retinopathy can lead to complications such as vitreous hemorrhage and retinal detachment.
Laser therapy to shrink and destroy abnormal blood vessels and surgery are some of the common treatments for proliferative diabetic retinopathy. Surgical interventions for proliferative retinopathy include a vitrectomy procedure to remove blood and scar tissue from the vitreous, and panretinal photocoagulation to preserve vision and prevent complications.
Adoption of sedentary lifestyles, lack of physical activities, poor diets, and high consumption of processed food increase the risk of various chronic diseases, especially diabetes. Type I and Type II diabetes may cause microvascular complications, leading to proliferative diabetic retinopathy. These complications can progress to sight-threatening stages, further causing blindness and visual impairment if not treated. Thus, rise in prevalence of diabetes among the population is contributing to the growth of the proliferative diabetic retinopathy industry.
According to the Centers for Disease Control and Prevention, diabetic retinopathy is projected to affect 16 million people with diabetes by 2050 in the U.S. Early detection and treatment can help avoid more than 90% of vision loss cases and intensive management of blood glucose levels can reduce the risk of diabetic retinopathy by 27%.
As per the proliferative diabetic retinopathy market forecast, growth in geriatric population across the globe is likely to propel market dynamics in the near future. The risk of developing diabetic retinopathy is higher in geriatric patients, especially those with a longer duration of diabetes. Geriatric patients may experience delays in the diagnosis of diabetic retinopathy due lack of awareness and delayed eye screenings.
Early detection, screening, and treatment help reduce the risk of proliferative diabetic retinopathy. Diagnostic advancements in diabetic eye care, such as micro-incision surgery, robot-assisted surgery, endoscopic visualization, sutureless surgery, and 3D visualization techniques help surgeons to diagnose and provide treatments efficiently. Hence, increase in adoption of advanced technologies in diabetic retinopathy surgical instruments is driving the proliferative diabetic retinopathy market revenue.
Moreover, increase in investments in gene therapy research in diabetic retinopathy is fueling the market progress. Gene therapy focuses on inhibiting abnormal vascular growth and modulating inflammation to restrict the progression of diabetic retinopathy. Healthcare organizations and research institutes are focusing on developing innovative gene therapies to effectively provide treatment for vision impairments.
According to the latest proliferative diabetic retinopathy market analysis, North America dominated the global market in 2022. Increase in awareness regarding diabetes and well-established healthcare facilities are likely to propel the proliferative diabetic retinopathy industry share during the forecast period. Favorable government initiatives and practitioner awareness are promoting eye care among the diabetic population.
According to the National Institutes of Health, about 440 million people in the age group 20-79 years are estimated to be suffering from diabetes mellitus worldwide which is around 7.7% by the year 2030. Thus, increase in prevalence of diabetes among people is augmenting market development in this region.
As per the latest proliferative diabetic retinopathy market trends, leading companies in the market are focusing on new product launches and drug development practices to improve their product portfolio. They are conducting clinical trials to receive approvals from government organizations to ensure the effectiveness and efficiency of the products.
Some of the players in the industry are Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, and Intas Pharmaceuticals Ltd.
These companies have been profiled in the proliferative diabetic retinopathy market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 2.5 Bn |
| Market Forecast (Value) in 2031 | US$ 5.2 Bn |
| Growth Rate (CAGR) | 8.5% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Tons | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 2.5 Bn in 2022
It is projected to register a CAGR of 8.5% from 2023 to 2031
Increase in prevalence of diabetes and technological advancements in diabetic retinopathy surgical instruments
North America was the most lucrative region in 2022
Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, and Intas Pharmaceuticals Ltd
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Proliferative Diabetic Retinopathy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Anti-VEGF Agents
6.3.2. Corticosteroids
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Mode of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Mode of Administration, 2017–2031
7.3.1. Injectable
7.3.2. Oral
7.3.3. Others
7.4. Market Attractiveness Analysis, by Mode of Administration
8. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Proliferative Diabetic Retinopathy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Anti-VEGF Agents
10.3.2. Corticosteroids
10.4. Market Value Forecast, by Mode of Administration, 2017–2031
10.4.1. Injectable
10.4.2. Oral
10.4.3. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Mode of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Anti-VEGF Agents
11.3.2. Corticosteroids
11.4. Market Value Forecast, by Mode of Administration, 2017–2031
11.4.1. Injectable
11.4.2. Oral
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Mode of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Anti-VEGF Agents
12.3.2. Corticosteroids
12.4. Market Value Forecast, by Mode of Administration, 2017–2031
12.4.1. Injectable
12.4.2. Oral
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Mode of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Anti-VEGF Agents
13.3.2. Corticosteroids
13.4. Market Value Forecast, by Mode of Administration, 2017–2031
13.4.1. Injectable
13.4.2. Oral
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Mode of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Anti-VEGF Agents
14.3.2. Corticosteroids
14.4. Market Value Forecast, by Mode of Administration, 2017–2031
14.4.1. Injectable
14.4.2. Oral
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Mode of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Genentech, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Regeneron Pharmaceuticals, Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pfizer Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Merck KGaA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Cipla Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. AbbVie Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Bausch Health Companies Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Santen Pharmaceutical Co., Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Alimera Sciences
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Intas Pharmaceuticals Ltd.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
List of Tables
Table 01: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031
Table 03: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031
Table 08: North America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031
Table 12: Europe Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031
Table 16: Asia Pacific Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031
Table 20: Latin America Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Mode of Administration, 2017–2031
Table 24: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Proliferative Diabetic Retinopathy Market Value Share, by Drug Class, 2022
Figure 04: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Mode of Administration, 2022
Figure 05: Global Proliferative Diabetic Retinopathy Market Value Share, by Mode of Administration, 2022
Figure 06: Global Proliferative Diabetic Retinopathy Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Proliferative Diabetic Retinopathy Market Value Share, by Distribution Channel, 2022
Figure 08: Global Proliferative Diabetic Retinopathy Market Value Share, by Region, 2022
Figure 09: Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 11: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 12: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031
Figure 13: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023-2031
Figure 14: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 15: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 16: Global Proliferative Diabetic Retinopathy Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 22: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031
Figure 23: North America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 24: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 25: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031
Figure 26: North America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 31: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031
Figure 32: Europe Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031
Figure 35: Europe Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 40: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031
Figure 41: Asia Pacific Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031
Figure 44: Asia Pacific Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 49: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031
Figure 50: Latin America Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 52: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031
Figure 53: Latin America Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Proliferative Diabetic Retinopathy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 58: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Mode of Administration, 2022 and 2031
Figure 59: Middle East & Africa Proliferative Diabetic Retinopathy Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Mode of Administration, 2023–2031
Figure 62: Middle East & Africa Proliferative Diabetic Retinopathy Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Proliferative Diabetic Retinopathy Market
*86 figures and 60 tables includes